A stem cell biologist, a gene editing expert, and a data engineer walk into a room…and that’s just a few of the people Daphne Koller has recruited in the past two years to Insitro. The South San Francisco-based startup has grand plans to reevaluate and, potentia...
Speeding up and bringing down the cost of clinical trials would be a huge boon to pharma companies and patients alike. San Francisco-based startup Unlearn.AI says it has developed proprietary technology that may help accomplish just that. On Monday the company announced...
Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together. San Francisco-based Atomwise has developed deep learning techniques for use i...
In startup world these days, the word “biotech” is increasingly accompanied by “computational” and two, two-letter initialisms: AI and ML. Those tools—artificial intelligence and machine learning, respectively—have been around for decades, but in rec...
Rare disease drug developer BridgeBio is now a public company, raising $348.5 million in the biggest biotech IPO so far this year. On Wednesday night, BridgeBio priced its stock offering of 20.5 million shares at $17 each, topping the $14 to $16 per share price range it...
It’s notoriously tough for experimental psychiatric drugs to succeed in clinical tests. BlackThorn Therapeutics wants to show that an AI-driven, precision approach can make it easier, and today it’s added another $76 million to get the chance to prove it. The new Se...
Alector, a company taking an immunotherapy approach to Alzheimer’s disease and other brain disorders, has raised approximately $176 million in an initial public offering. The South San Francisco, CA, biotech sold 9.25 million shares Wednesday evening priced at $19 api...
Virta Health, a startup that is taking a software approach to treating diabetes rather than pills or injections, has raised $45 million in funding to support its technology. San Francisco-based Virta says its software “reverses” diabetes through behavioral changes t...
Drug discovery startup twoXAR has raised $10 million in funding to support its efforts to build a pipeline of drug candidates found by its proprietary artificial intelligence technology. SoftBank Ventures led the Series A round of financing, and was joined by the Andree...
Engine Biosciences has raised $10 million in funding to further develop its artificial intelligence-based drug discovery tool. DHVC and 6 Dimensions Capital co-led the seed investment in the San Francisco-based company. Joining in the investment were WuXi AppTec, EDBI, ...